Dalen-Fuchs nodules: Seen in a minority; not pathognomonic
Enucleation after onset: Does not help the sympathising eye
Sympathetic ophthalmia is a rare bilateral granulomatous panuveitis that follows penetrating injury or surgery to one eye. The injured eye is the "exciting" eye and the other is the "sympathising" eye. Early, strong immunosuppression saves sight.
How common, and when?
After penetrating trauma: about 0.2–0.5%; after intraocular surgery much rarer (around 0.01%), with vitreoretinal surgery now an important cause.
Half of cases start within 3 months and 90% within a year, but it can appear decades later.
Clinical features
Both eyes: blurred vision, photophobia, reduced accommodation in the sympathising eye.
Exclude infection (syphilis, TB) before high-dose immunosuppression.
Treatment
High-dose systemic steroids (oral prednisolone 1–2 mg/kg/day, or IV methylprednisolone 1 g/day for 3 days in severe disease), tapered slowly over at least 3 months.
Most patients need a steroid-sparing immunosuppressant (ciclosporin, mycophenolate, azathioprine, or biologics such as adalimumab).
Starting treatment within about 2 weeks of symptoms is associated with better vision.
The enucleation question
Enucleation of a blind, severely injured eye within 2 weeks of injury was historically thought to prevent sympathetic ophthalmia; the evidence is weak, and primary repair with an attempt to save the eye is now standard.
Once sympathetic ophthalmia has started, removing the exciting eye does not help the sympathising eye, and the exciting eye may end up the better one.
Where residents slip
Forgetting to ask about old injuries or eye surgery in bilateral granulomatous uveitis.
Enucleating the exciting eye after onset to "cure" the disease.
Patel D. Sympathetic Ophthalmia: Recognition, Treatment and the Enucleation Question. RPC Rounds (Sadbhaav Eye Clinic). Updated November 2026. Available at: https://www.sadbhaavclinic.com/sympathetic-ophthalmia.html. Accessed [date].
Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy